| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL11Ra |
| Uniprot No | Q14626 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-422aa |
| 氨基酸序列 | MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPG VTAGDPVSWFRDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGA LGGTVTLQLGYPPARPVVSCQAADYENFSCTWSPSQISGLPTRYLTSYRK KTVLGADSQRRSPSTGPWPCPQDPLGAARCVVHGAEFWSQYRINVTEVNP LGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASWTYPASWPCQP HFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD AGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSL QPHPRLLDHRDSVEQVAVLASLGTLSFLGLVAGALALGLWLRLRRGGKDG SPKPGFLASVIPVDRRPGAPNL |
| 预测分子量 | 72 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL11Ra重组蛋白的参考文献及其摘要概括：
1. **文献名称**: "IL-11 receptor alpha-mediated signaling regulates fibrosis and stem cell activation in muscular dystrophy"
**作者**: Klein et al.
**摘要**: 研究利用重组IL11Ra蛋白阻断IL-11信号，发现其可减轻肌肉纤维化并促进卫星细胞再生，为肌营养不良治疗提供新靶点。
2. **文献名称**: "Structural basis of IL-11 recognition by IL-11Ra and implications for antagonist design"
**作者**: Wang et al.
**摘要**: 通过晶体结构解析重组IL11Ra蛋白与IL-11的结合机制，揭示关键互作界面，为开发抑制IL-11信号通路的小分子药物奠定基础。
3. **文献名称**: "Recombinant IL-11Ra attenuates pulmonary fibrosis via inhibiting epithelial-mesenchymal transition"
**作者**: Zhang et al.
**摘要**: 在小鼠肺纤维化模型中，重组IL11Ra蛋白通过阻断IL-11信号，显著抑制上皮间质转化(EMT)，减少胶原沉积和病理损伤。
注：以上文献信息为示例性内容，实际文献需通过学术数据库检索确认。建议使用PubMed或Web of Science以关键词“IL11Ra recombinant”查询最新研究。
Interleukin-11 receptor alpha (IL11Ra) is a key component of the interleukin-11 (IL-11) signaling pathway, which regulates diverse biological processes including hematopoiesis, tissue regeneration, inflammation, and cellular homeostasis. As a transmembrane protein, IL11Ra forms a functional receptor complex with the signal-transducing subunit glycoprotein 130 (gp130). IL-11 binds specifically to IL11Ra, triggering gp130 dimerization and activation of downstream signaling cascades such as JAK/STAT, MAPK, and PI3K/AKT pathways. Dysregulation of IL-11/IL11Ra signaling has been implicated in pathologies like fibrosis, cancer progression, and inflammatory disorders.
Recombinant IL11Ra protein is engineered in vitro using expression systems (e.g., mammalian CHO cells or *E. coli*) to produce soluble forms of the receptor extracellular domain. This recombinant protein retains the ability to bind IL-11 with high affinity, making it a valuable tool for studying IL-11-mediated mechanisms or developing therapeutic strategies. For instance, soluble IL11Ra can act as a decoy receptor to neutralize IL-11 activity, offering potential in treating IL-11-driven diseases. Researchers also utilize recombinant IL11Ra in structural studies to map ligand-receptor interactions and in cell-based assays to modulate signaling for functional genomics.
Recent studies highlight IL11Ra’s role in fibrotic diseases and epithelial malignancies, where its overexpression correlates with poor prognosis. However, challenges remain in achieving tissue-specific targeting and minimizing off-target effects. Ongoing research focuses on optimizing recombinant IL11Ra for clinical applications, including fusion proteins or antibody conjugates to enhance pharmacokinetics. Advances in structural biology and receptor-ligand dynamics continue to refine its therapeutic potential, positioning recombinant IL11Ra as a promising candidate for precision medicine in IL-11-associated disorders.
×
